Last $1.84 USD
Change Today +0.02 / 1.10%
Volume 392.1K
FOLD On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

amicus therapeutics inc (FOLD) Snapshot

Open
$1.80
Previous Close
$1.82
Day High
$1.91
Day Low
$1.80
52 Week High
05/22/13 - $3.79
52 Week Low
04/16/14 - $1.77
Market Cap
114.6M
Average Volume 10 Days
738.3K
EPS TTM
$-1.15
Shares Outstanding
62.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AMICUS THERAPEUTICS INC (FOLD)

amicus therapeutics inc (FOLD) Related Bloomberg News

View More Bloomberg News

amicus therapeutics inc (FOLD) Related Businessweek News

No Related Businessweek News Found

amicus therapeutics inc (FOLD) Details

Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. It develops enzyme replacement therapies (ERTs) for lysosomal storage disorders (LSDs), including Fabry disease, Pompe disease, and Mucopolysaccharoidosis Type I (MPS I). The company also develops novel small molecules as monotherapy treatments for Fabry disease and Parkinson's disease. Its chaperone-advanced replacement therapy program is used to develop next-generation ERTs by co-formulating therapeutic enzymes with proprietary pharmacological chaperones. The company’s lead programs include the small molecule pharmacological chaperones, migalastat HCl as a monotherapy that is in Phase III global registration studies for Fabry patients with genetic mutations; and AT2220 (duvoglustat HCl), which has completed Phase II safety used for the treatment of Pompe disease. Its products also comprise AT-B200, a proprietary recombinant human acid-alpha glucosidase that is in late preclinical development for Pompe disease; and AT3375 for treating Gaucher disease. The company has strategic collaboration with GlaxoSmithKline PLC to develop and commercialize migalastat HCl. Amicus Therapeutics, Inc. was founded in 2002 and is based in Cranbury, New Jersey.

92 Employees
Last Reported Date: 03/3/14
Founded in 2002

amicus therapeutics inc (FOLD) Top Compensated Officers

Chairman and Chief Executive officer
Total Annual Compensation: $847.6K
Chief Financial Officer
Total Annual Compensation: $377.5K
Chief Operating Officer
Total Annual Compensation: $457.6K
Principal Accounting Officer, Vice President ...
Total Annual Compensation: $247.4K
Compensation as of Fiscal Year 2012.

amicus therapeutics inc (FOLD) Key Developments

Amicus Therapeutics, Inc. Presents at 13th Annual Needham Healthcare Conference, Apr-09-2014 03:40 PM

Amicus Therapeutics, Inc. Presents at 13th Annual Needham Healthcare Conference, Apr-09-2014 03:40 PM. Venue: The Westin Grand Central Hotel, New York, New York, United States. Speakers: John F. Crowley, Chairman and Chief Executive Officer.

Amicus Mulls Acquisitions

Amicus Therapeutics, Inc. (NasdaqGM:FOLD) is looking for acquisitions. Amicus has filed a follow on equity offering in the amount of $40 million. The proceed of which will be used for working capital and general corporate purposes, which may include, without limitation, research and development expenses, including preclinical study and clinical trial costs; capital expenditures; the funding of in-licensing agreements for product candidates, additional technologies or other forms of intellectual property; the acquisition of assets or businesses that are complementary to our existing business; and general and administrative expenses.

Amicus Therapeutics, Inc. Announces Executive Changes

Amicus Therapeutics announced the appointment of Jay A. Barth, MD as Chief Medical Officer, effective on March 3, 2014. Dr. Barth brings to Amicus more than 15 years of experience in drug development, clinical research and medical affairs. In his role as Chief Medical Officer, he will be responsible for all clinical development activities as well as regulatory affairs. The company also announced the promotion of Bradley L. Campbell from Chief Business Officer to Chief Operating Officer, effective December 2013. Both Dr. Barth and Mr. Campbell report to John F. Crowley, Chairman and Chief Executive Officer of Amicus. Prior joining Amicus, Dr. Barth held roles of increasing responsibility at PTC Therapeutics, Inc. from 2009 to 2014. He most recently served as PTC's Senior Vice President, Clinical Development. In this role he led the clinical team and oversaw all global clinical development programs, focusing on rare diseases including Duchenne Muscular Dystrophy and Cystic Fibrosis. Mr. Campbell has over a decade of experience in the rare and orphan disease field at both Amicus and Genzyme. He joined Amicus in 2006 and has assumed positions of increasing responsibility, most recently serving as Chief Business Officer. In his new role, Mr. Campbell will remain the head of several departments including Business Development, Program Management, Commercial Planning, Patient and Professional Advocacy, and Technical Operations, with increased responsibility in overseeing preclinical research and development.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FOLD:US $1.84 USD +0.02

FOLD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FOLD.
View Industry Companies
 

Industry Analysis

FOLD

Industry Average

Valuation FOLD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 284.7x
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 49.8x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMICUS THERAPEUTICS INC, please visit www.amicustherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.